CompletedPhase 3NCT04414241

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Universidad Peruana Cayetano Heredia
Principal Investigator
Alejandro Llanos, MD, PhD
Universidad Peruana Cayetano Heredia
Intervention
Hydroxychloroquine(drug)
Enrollment
68 target
Eligibility
18 years · All sexes
Timeline
20202020

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04414241 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials